Similarly, chronic angiotensin receptor blockade in the current CKD model resulted in the reduction of efferent resistance, glomerular pressure, albuminuria, and chronic GFR decline; and importantly, the addition of SGLT2 inhibition further improved these parameters (Figure S5). The gene discussed is SLC5A2; the disease is chronic kidney disease.